NSCLC brain metastasis survival prediction method patent granted

USPTO granted patent US12594024B2 on April 7, 2026, to THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION for a method of predicting survival of non-small cell lung cancer patients with brain metastasis. The patent covers comparing patient TMTrg values against cut-off values for long-term survival prediction using medical imaging analysis.

Method and system for assisting a user in guiding a catheter during a cardial operation

The USPTO granted Patent US12594018B2 to Biosense Webster (Israel) Ltd. for a method and system assisting catheter guidance during cardiac procedures. The patent covers dynamically identifying displaced portions of a catheter distal end assembly using electrical information from electrodes, generating and warping visual representations for display. The patent contains 20 claims and was filed on May 20, 2024.

NEC patent for endoscopic lesion detection using heat maps

NEC patent for endoscopic lesion detection using heat maps

Endoscope Treatment Tool - US12593959B2

USPTO granted patent US12593959B2 to Olympus Medical Systems Corp. for an endoscope treatment tool featuring a sheath with a first channel and an incision device with a second channel. The invention enables switching between two modes to form different fluid paths between the main flow chamber and the respective channels. The patent contains 13 claims.

Endoscope with Fluid Flow Circuit Closure Device for Improved Sterilisation

The USPTO granted patent US12593960B2 to AXESS VISION TECH for a medical endoscope featuring a piston-based fluid flow circuit closure device. The invention includes a sealed obturation section and interconnection chamber designed to limit pressure drop during circuit operation. The patent covers 11 claims and protects the assignee's proprietary fluid closure mechanism intended to improve sterilisation of endoscopic equipment.

Apparatus and Methods for Screening, Diagnosis and Monitoring of Respiratory Disorders

The USPTO granted ResMed Pty Ltd Patent US12594025B2 covering a medical device that uses ECG sensors, accelerometers, and photoplethysmographs (PPG) to detect sleep-disordered breathing (SDB) events. The patent includes 20 claims and covers methods for screening, diagnosis, and monitoring of respiratory disorders using multi-sensor signal analysis.

T cell receptors for mesothelin cancer immunotherapy

The USPTO granted patent US12595290B2 to Fred Hutchinson Cancer Center covering binding proteins (T cell receptors) specific for mesothelin peptides Msln20-28 and Msln530-538, along with compositions and recombinant host cells for cancer immunotherapy. The patent protects methods for treating mesothelioma, pancreatic cancer, ovarian cancer, and lung cancer using these binding proteins.

BIG3-PHB2 Interaction-Inhibiting Peptide Therapeutic Agent for Breast Cancer

USPTO granted patent US12595289B2 to Tokushima University for a therapeutic peptide that inhibits BIG3-PHB2 protein interaction, designed specifically for treating estrogen receptor-positive breast cancer. The peptide selectively targets BIG3-overexpressing cancer cells while avoiding expression of side effects. The patent covers 6 claims including the peptide composition and pharmaceutical formulation.

Anti-follicle stimulating hormone receptor antibodies and methods of treatment

USPTO granted Patent US12595293B2 to The Wistar Institute covering isolated antibodies and antigen-binding fragments that specifically bind to Follicle Stimulating Hormone Receptor (FSHR), along with methods for treating diseases by administering these antibodies. The patent includes 14 claims and covers compositions for cancer treatment applications.

Dosing regimes for treatment of synucleinopathies

USPTO granted patent US12595295B2 to Prothena Biosciences Limited covering antibody dosing regimes for treatment of synucleinopathies. The patent specifies intravenous antibody dosing of 3000-5000 mg or 1300-1700 mg every 3-5 weeks. This grant provides exclusive intellectual property rights for these therapeutic dosing protocols.